belantamab mafodotin
Selected indexed studies
- Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. (N Engl J Med, 2024) [PMID:38828933]
- Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. (N Engl J Med, 2024) [PMID:38828951]
- Belantamab Mafodotin. (, 2012) [PMID:38154014]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. (2024) pubmed
- Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. (2024) pubmed
- Belantamab Mafodotin. (2012) pubmed
- Belantamab Mafodotin: First Approval. (2020) pubmed
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. (2020) pubmed
- Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. (2023) pubmed
- Belantamab-mafodotin-associated keratopathy. (2024) pubmed
- Belantamab mafodotin in multiple myeloma. (2023) pubmed
- Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. (2023) pubmed
- The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development. (2025) pubmed